Nervous Disorder TRIZ Cases

Palmitoylethanolamide combined with vitamin B complex provides targeted analgesic action.

Hydrophilic modification of the antigen enables high-affinity detection of T4 while minimizing cross-reactivity with halogenated bisphenol A.

A pharmaceutical composition containing an APL type peptide and stabilizing sugars regulates immune responses to treat inflammatory diseases.

Substituents at carbons 1 and 2 block beta-oxidation in 1,2-derivatives of polyunsaturated fatty acids, extending blood half-life beyond natural limits.

A multistep extraction process using methyl ethyl ketone and n-heptane to isolate specific Ginkgo biloba components.

Protease-activatable bispecific proteins extend half-life while preventing systemic side effects through localized tumor activation.

A human monoclonal antibody targets the JC virus VP1 protein to neutralize infection and enable diagnostic detection.

Autologous placental stem cells differentiate into neural tissue to reverse incurred injury and preserve spinal cord structure.

Metformin inhibits Protein Kinase R to reduce toxic RAN protein accumulation, addressing inadequate therapeutic strategies for neurological diseases.

Cyclic phosphatidic acids treat demyelinating diseases by suppressing axon damage where conventional agents fail.

Oligopeptides neutralize epitope-specific anti-MBP catalytic autoantibodies, suppressing myelin degradation and clinical symptoms without adverse immune events.

Lactobacillus brevis SBC8803 cells normalize clock gene mRNA expression, resolving dependency risks from pharmacological treatments.

Combining acamprosate with casein or soy protein isolates mitigates gastrointestinal side effects while maintaining therapeutic plasma levels.

Thiosemicarbazone compounds inhibit oxidative stress and excitotoxicity to provide neuroprotection.